Remdesivir experience in patients diagnosed with COVID-19 in a tertiary hospital

Ayşegül Seremet Keskin; Kübra Demir Önder; Filiz Kızılateş

Makale detayları

Remdesivir experience in patients diagnosed with COVID-19 in a tertiary hospital

Yazarlar:

Ayşegül Seremet Keskin | Kübra Demir Önder | Filiz Kızılateş

Yayıncı:

Pamukkale University

Ana Başlıklar:

Bulaşıcı Hastalıklar

Dergi:

Pamukkale Tıp Dergisi Vol.16 Issue 1, pp.1-7

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001281222

pISSN:

1308-0865

Anahtar kelimeler:

Özet:

 Purpose: Remdesivir is an adenosine nucleotide analog antiviral drug recommended in these treatment combinations. While vaccine and drug studies are underway in the treatment of COVID-19, remdesivir is also being studied in terms of efficacy, safety, and potential side effects. Therefore, we aimed to share our experiences of patients who were diagnosed with COVID-19 and treated with remdesivir in our hospital. Material method: Patients over 18 years of age, who were diagnosed with COVID-19 in our hospital between March 15 and March 30, 2020, based on positive RT-PCR andor thoracic computed tomography CT results studied from nasopharyngeal samples, were screened retrospectively. Those who had received Remdesivir treatment were included in our study. Results: 23 patients were included in our study. Eighteen 79.2 of the patients were male and 5 20.8 were female. Remdesivir initiation time was 8.42.6 days from the onset of symptoms and 62.6 days from the time of diagnosis. In the follow-up period, we had to hospitalize 18 patients 78.2 in the intensive care unit ICU. 14 60.8 needed a mechanical ventilator. Post-treatment follow-up showed that 15 65.2 recovered, and 8 34.8 resulted in mortality. Conclusion: Since inflammation is as critical as the replication of the virus in the pathogenesis of COVID-19 disease, the use of remdesivir in combination with other antiviral and anti-cytokine therapies may increase the effectiveness. We believe that we need new studies in this regard.

 Purpose: Remdesivir is an adenosine nucleotide analog antiviral drug recommended in these treatment combinations. While vaccine and drug studies are underway in the treatment of COVID-19, remdesivir is also being studied in terms of efficacy, safety, and potential side effects. Therefore, we aimed to share our experiences of patients who were diagnosed with COVID-19 and treated with remdesivir in our hospital. Material method: Patients over 18 years of age, who were diagnosed with COVID-19 in our hospital between March 15 and March 30, 2020, based on positive RT-PCR andor thoracic computed tomography CT results studied from nasopharyngeal samples, were screened retrospectively. Those who had received Remdesivir treatment were included in our study. Results: 23 patients were included in our study. Eighteen 79.2 of the patients were male and 5 20.8 were female. Remdesivir initiation time was 8.42.6 days from the onset of symptoms and 62.6 days from the time of diagnosis. In the follow-up period, we had to hospitalize 18 patients 78.2 in the intensive care unit ICU. 14 60.8 needed a mechanical ventilator. Post-treatment follow-up showed that 15 65.2 recovered, and 8 34.8 resulted in mortality. Conclusion: Since inflammation is as critical as the replication of the virus in the pathogenesis of COVID-19 disease, the use of remdesivir in combination with other antiviral and anti-cytokine therapies may increase the effectiveness. We believe that we need new studies in this regard.

 Purpose: Remdesivir is an adenosine nucleotide analog antiviral drug recommended in these treatment combinations. While vaccine and drug studies are underway in the treatment of COVID-19, remdesivir is also being studied in terms of efficacy, safety, and potential side effects. Therefore, we aimed to share our experiences of patients who were diagnosed with COVID-19 and treated with remdesivir in our hospital. Material method: Patients over 18 years of age, who were diagnosed with COVID-19 in our hospital between March 15 and March 30, 2020, based on positive RT-PCR andor thoracic computed tomography CT results studied from nasopharyngeal samples, were screened retrospectively. Those who had received Remdesivir treatment were included in our study. Results: 23 patients were included in our study. Eighteen 79.2 of the patients were male and 5 20.8 were female. Remdesivir initiation time was 8.42.6 days from the onset of symptoms and 62.6 days from the time of diagnosis. In the follow-up period, we had to hospitalize 18 patients 78.2 in the intensive care unit ICU. 14 60.8 needed a mechanical ventilator. Post-treatment follow-up showed that 15 65.2 recovered, and 8 34.8 resulted in mortality. Conclusion: Since inflammation is as critical as the replication of the virus in the pathogenesis of COVID-19 disease, the use of remdesivir in combination with other antiviral and anti-cytokine therapies may increase the effectiveness. We believe that we need new studies in this regard.

 Amaç: Remdesivir, COVID-19 tedavi kombinasyonlarında önerilen bir adenozin nükleotid analogu antiviral bir ilaçtır. COVID-19 tedavisinde aşı ve ilaç çalışmaları devam ederken, remdesivir de etkinlik, güvenlik ve olası yan etkiler açısından incelenmektedir. Bu nedenle hastanemizde COVID-19 tanısı alan ve remdesivir ile tedavi edilen hastalarımızın deneyimlerimizi paylaşmayı amaçladık. Gereç ve yöntem: 15 Mart-30 Mart 2020 tarihleri arasında, hastanemize başvuran ve nazofarengeal örneklerden çalışılan RT-PCR testi pozitif olan veveya toraks bilgisayarlı tomografi BT sonuçlarına göre COVID-19 tanısı alan 18 yaş üstü hastalar retrospektif olarak tarandı. Remdesivir tedavisi alanlar çalışmamıza dahil edildi. Bulgular: Çalışmamıza 23 hasta dahil edildi. Hastaların 18i 79,2 erkek, 5i 20,8 kadındı. Remdesivir başlama süresi semptomların başlangıcından itibaren 8,42,6 gün ve tanı anından itibaren 62,6 gündü. Takip döneminde 18 hastayı 78,2 yoğun bakım ünitesine YBÜ yatırmak zorunda kaldık. 14ünde 60,8 mekanik ventilatöre ihtiyaç duydu. Tedavi sonrası takiplerinde ise 15 hastanın 65,2 taburcu edildiği ve 8 hastanın 34,8 ölümle sonuçlandığını gösterildi. Sonuç: COVID-19 hastalığının patogenezinde virüsün replikasyonu kadar inflamasyon da önemli olduğundan remdesivirin diğer antiviral, antisitokin tedaviler ile kombine şekilde kullanımı ile etkinliğinde artış olabileceği ve bu konuda da yapılacak yeni çalışmalara ihtiyaç olduğu düşünülmüştür.

Makale detayları

Remdesivir experience in patients diagnosed with COVID-19 in a tertiary hospital

Yazarlar: Ayşegül Seremet Keskin | Kübra Demir Önder | Filiz Kızılateş

Yayıncı: Pamukkale University

Ana Başlıklar: Bulaşıcı Hastalıklar

Dergi: Pamukkale Tıp Dergisi Vol.16 Issue 1, pp.1-7

Belge Tipi: Makale

Yayın Tarihi: 1/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001281222

pISSN: 1308-0865

COVID-19

remdesivir

treatment

COVID-19

remdesivir

tedavi

Sayı

Yazarlar:

Ayşegül Seremet Keskin | Kübra Demir Önder | Filiz Kızılateş

Yayıncı:

Pamukkale University

Ana Başlıklar:

Bulaşıcı Hastalıklar

Dergi:

Pamukkale Tıp Dergisi Vol.16 Issue 1, pp.1-7

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001281222

pISSN:

1308-0865